Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 3/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593663 | 0.91 | SYK (0.49) | SQORSYKHPGDALOX5KDM5A | |
| SCHEMBL14390896 | 0.88 | HPGD (0.42) | SYKHPGDALOX5FFAR1 | |
| SCHEMBL3580685 | 0.86 | PDE5A (0.48) | SQORHPGDPIM1ALDH1A1 | |
| SCHEMBL3592445 | 0.85 | SQOR (0.47) | SQORACMSDHPGDPIM1MAPK8 | |
| SCHEMBL13545980 | 0.84 | HDAC1 (0.41) | ACMSDHPGDKDM4CIKBKBMAPK8 | |
| SCHEMBL3583516 | 0.81 | SQOR (0.46) | SQORHPGDPIM1KDM4CIKBKB | |
| SCHEMBL3586498 | 0.79 | SQOR (0.49) | SQORHPGDALDH1A1 | |
| SCHEMBL3585039 | 0.78 | SQOR (0.46) | SQORSYKHPGDPIM1MAPK8 | |
| Tromethamine SCHEMBL3584251 | 0.78 | SQOR (0.43) | SQORHPGDPIM1KDM4CIKBKB | |
| SCHEMBL3587275 | 0.78 | KMT2A (0.46) | SQORACMSDHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | AVEXA LIMITED (AU) | 2010-01-14 | — | — | US | disclosed |
| WO-2007124546-A1 | INTEGRASE INHIBITORS 3 | AVEXA LIMITED (AU) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009973-A1 | Integrase Inhibitors 3 | TYMP, IMPDH1, IMPDH2 | SQOR 3669/4885SYK 952/4885ACMSD 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.